Replies to post #473530 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Hope: as close as I can tell it is 20% at the true 36 months. Just type into Google 2018 Linda Liau paper and it comes up

You are talking about the 2018 JTM paper with data from early 2017. Not the 2018 SNO presentation by LL that was based on data from Oct 2018.

The K/M on 2018 SNO was only captured on camera unfortunately. But the 3y post surgery OS number was presented as 28.2% (vs 25,4% in the dataset you are looking at). The SNO data was virtually complete for 36 months.

[ATLnsider]

biotrade49, you make some very good points, especially in regards to the blinded ITT data was plotted from the time of surgery, compared to the unblinded data being plotted from the time of randomization.

As you know, randomization is only relevant in a clinical trial setting. In the real-world, outside of a clinical trial, patients diagnosed with GBM are not randomized, they are only treated with the current standard of care (SOC).

In the real-world overall survival is counted from GBM diagnosis or from the time of surgery. In my opinion, I believe that neuro-oncologists, neuron-surgeons, and other clinicians who treat GBM patients (outside of a clinical trial) will focus more on the DCVax-L 22.4 months OS number from surgery, as the real-world survival number.